SCHEMBL204638

SCHEMBL204638

CC(=O)N[CH]CCCCC=O

nearest known ligand 0.41

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.41
HIF1A Q16665 2/20 0.39
FAAH O00519 2/20 0.37
TRPV1 Q8NER1 2/20 0.37
MAPT P10636 1/20 0.33
KDM4E B2RXH2 1/20 0.31
MAPK1 P28482 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL798306 0.82 CNR1 (0.33) HIF1AMAPTKDM4EMAPK1
SCHEMBL1556426 0.82 EP300 (0.42) TSHRFAAHMAPTMAPK1
SCHEMBL10886696 0.80 EP300 (0.45) TSHRFAAHMAPTMAPK1
SCHEMBL10893304 0.80 EP300 (0.45) TSHRFAAHMAPTMAPK1
SCHEMBL10531391 0.80 EP300 (0.45) TSHRFAAHMAPTMAPK1
SCHEMBL798325 0.79
SCHEMBL8323964 0.78 KDM4E (0.60) TSHRHIF1AKDM4EMAPK1ALDH1A1
SCHEMBL17074293 0.77 ADRA1A (0.52) TSHRFAAHMAPT
Acetic Acid SCHEMBL29740586 0.75 HIF1A (0.53) TSHRHIF1AFAAHTRPV1MAPT
SCHEMBL998029 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162435-B1 Ionic liquids as electrolytes INVISTA TECH SARL (CH) 2013-09-04 EP disclosed
US-20120190844-A1 IONIC LIQUIDS INVISTA NORTH AMERICA S.A R.L. (US) 2012-07-26 US disclosed
US-8088917-B2 Ionic liquids INVISTA NORTH AMERICA S.A R.L. (US) 2012-01-03 US disclosed
EP-2162435-A1 IONIC LIQUIDS AS ELECTROLYTES Invista Technologies S.A.R.L. (US) 2010-03-17 EP disclosed
WO-2008150842-A1 IONIC LIQUIDS AS ELECTROLYTES INVISTA TECHNOLOGIES S.A.R.L. (US) 2008-12-11 WO disclosed
US-20080296531-A1 IONIC LIQUIDS INVISTA NORTH AMERICA S.A R.L. (US) 2008-12-04 US disclosed
EP-0783479-B1 CONVERSION OF NYLON 6 AND/OR NYLON 6,6 TO ADIPIC ACID DU PONT (US) 1999-10-06 EP disclosed
EP-0783479-A1 CONVERSION OF NYLON 6 AND/OR NYLON 6,6 TO ADIPIC ACID E.I. DU PONT DE NEMOURS AND COMPANY (US) 1997-07-16 EP disclosed
WO-1996010008-A1 CONVERSION OF NYLON 6 AND/OR NYLON 6,6 TO ADIPIC ACID E.I. DU PONT DE NEMOURS AND COMPANY (US) 1996-04-04 WO disclosed
US-5468900-A Conversion of nylon 6 and/or nylon 6,6 to adipic acid E. I. DU PONT DE NEMOURS AND COMPANY (US) 1995-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190844-A1 IONIC LIQUIDS INF2, H1-2, H1-0 TSHR 1497/4885HIF1A 3278/4885FAAH 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.